HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Naoki Takegawa 1 , Kimio Yonesaka 1 , Kazuko Sakai 2 , Hiroto Ueda 1 , Satomi Watanabe 1 , Yoshikane Nonagase 1 , Tatsuya Okuno 1 , Masayuki Takeda 1 , Osamu Maenishi 3 , Junji Tsurutani 1 , Taroh Satoh 4 , Isamu Okamoto 5 , Kazuto Nishio 2 , Takao Tamura 1 , and Kazuhiko Nakagawa 1 1 Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan 2 Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan 3 Department of Pathology, Kinki University School of Medicine, Osaka, Japan 4 Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan 5 Center for Clinical and Translational Research, Kyushu University, Kyushu, Japan Correspondence to: Kimio Yonesaka, e-mail: yonesaka@sakai.med.kindai.ac.jp Keywords: colorectal cancer, cetuximab, acquired resistance, human epidermal growth factor receptor 2, ctDNA Received: August 21, 2015 Accepted: November 21, 2015 Published: December 02, 2015 ABSTRACT Background: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one of the mechanisms conferring resistance to anti-EGFR antibody therapy and could therefore be a potential therapeutic target. The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) from patients with CRC and acquired resistance to anti-EGFR antibody therapy. Results: Our data showed that 22% (4/18) of patients in the cohort exhibited HER2 amplification. One of these patients was found to be positive for HER2 amplification in matched tumor specimens collected after cetuximab therapy, at which point the patient had acquired cetuximab resistance, despite being negative for HER2 amplification prior to therapy. Methods: We analyzed plasma ctDNA using digital polymerase chain reaction (PCR) from 18 patients with CRC, who had been treated with anti-EGFR antibody-based therapy (cetuximab) and subsequently acquired resistant cetuximab. HER2 gene copy number was analyzed using fluorescence in situ hybridization in tumor samples before and after acquisition of resistance to cetuximab-based therapy. Conclusion: Analysis of plasma ctDNA by digital PCR could be useful for detecting HER2 amplification in patients with CRC who were resistant to anti-EGFR antibody therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 3×
“Other studies have reported the emergence of mutant KRAS alleles or MET amplification following anti-EGFR antibody therapy in patients with CRC [9][22].”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 2×
“For example, a previous study detected the development of KRAS mutations in ctDNA from some patients with CRC who had been treated with antiEGFR antibody therapy [14].”
BackgroundResultBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 1×
“8% at the time of CRC diagnosis [15][21].”
BackgroundActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Self-citationAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 1×
“Alternatively, EGFR ectodomain mutations, such as S492R, have been shown to prevent anti-EGFR antibodies, particularly cetuximab, from binding with EGFR, thereby conferring resistance to this therapy [11].”
Background
Cited by
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351354 · Cited by 95
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8
Metadata
- Authors
- Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., Satoh, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-12-02
- Volume
- 7
- Issue
- 3
- Pages
- 3453-3460
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2220166442
- Cited by
- 70
- References
- 9
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.6498
- The paper
- Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., Satoh, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K. (2016). HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.6498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.